Exchange: NASDAQ·Updated 04:17 PM EDT
IFRX logo

IFRX InflaRx N.V.

$2.42
$0.13
(6.02%)
Today
Closed $2.29
$0.13
(5.68%)
After Hours
Reported EarningsAug 6
Mkt Cap$318.32M
Vol567,840.00

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
55

Bullish Sentiment

How do you feel about IFRX?

Advertisement|Remove ads.